Beamtree Holdings Ltd · ASX:BMT
Beamtree — FY2024 Earnings Presentation
30 slides from Beamtree's earnings presentation, Aug 27, 2024
Slide 1: FY24: Strong cashflow and FY25 outlook
FY24: Strong cashflow and FY25 outlook FY24 Audited Annual Results 27 August 2024 Authorised for release by the Chairperson of the Board
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer The material in this presentation is general background information about Beamtree Holdings Limited (ASX:BMT) and is current at the date of the presentation, 27 August 2024. This presentation may contain statements that are, or may be deemed to be, forward looking sta
Slide 3: FY24 Highlights
FY24 Highlights Copyright © Beamtree Holdings Limited – All Rights Reserved 2
Slide 4: FY24 Financial Highlights
FY24 Financial Highlights 12% 21% 47% 129% $5.0M PCP* PCP PCP PCP Annual recurring Reported Revenue International Operating Profit Cash Revenue Revenue $25.5M $27.6M $10.7M $0.4M ~Cashflow break even 39% of total revenue in 2H FY24 **Prior Corresponding Period “PCP” Copyright © Beamtree Holdings Lim
Slide 5: Annual Recurring Revenue (ARR) Trend
Annual Recurring Revenue (ARR) ($’M) Trend 40% CAGR 25 25.5 23.8 24.2 ~$60M 22.8 21 20.1 19.1 18.2 16.8 17.3 $25.5M FY23 2026 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 Diagn. Coding CDS KN Copyright © Beamtree Holdings Limited – All Rights Reserved 4
Slide 6: FY24 Highlights
FY24 Highlights • Deepened our relationships in core target geographies • Maturing partnerships with Abbott and Lean • Enhanced focus on cross selling, pricing discipline and driving higher value recurring revenue • Significant investment in product development aimed at enhancing product ROI, produc
Slide 7: Long Term Horizon – Reaffirm Conviction
Long Term Horizon – Reaffirm Conviction Main Drivers of Growth: +40% $60M ~70% of the growth will come from CAGR overseas market Abbott (3+2 year) contract with pipeline and momentum growing International direct RippleDown sales, pipeline growing with UK main focus in FY25 + FY26 $25.5M $22.8M Sales
Slide 8: Beamtree Strategy
Beamtree Strategy Copyright © Beamtree Holdings Limited – All Rights Reserved 7
Slide 9: Creating a better future for health – About Us
Creating a better future for health We provide AI decision support and data insights solutions with the aim of turning data into insights and action through automation. We believe it starts with better data and ends in better care – and that ‘better has no limit’ About Us 25+ years of Australian Sup
Slide 10: Beamtree is committed to supporting learning health systems
Beamtree is committed to supporting learning health systems Driving continuous improvement by better access to healthcare information – towards safety, quality and efficiency.
Slide 11: The Problems We Help Solve
The Problems We Help Solve Tackle unwarranted Offer revenue Promote Drive variation assurance transparency automation Address equity Bridge knowledge gaps Increase efficiency, Improve quality of access and resource reducing errors of data allocation Copyright © Beamtree Holdings Limited – All Rights
Slide 12: Our product segments
Our product segments Copyright © Beamtree Holdings Limited – All Rights Reserved 11
Slide 13: Key Areas, Key Products and What They Do
Key Areas, Key Products and What They Do Product/ Solutions Application Problem Solved ROI Pricing/Scale Clinical rules to automate Leverages scarce clinical resources Removes duplication for experts Recurring License + volume expert decision making in through automating and in providing diagnostic
Slide 14: Beamtree's AI Product Innovation: Coding Deep Dive (1 of 3)
Beamtree's AI Product Innovation: Coding Deep Dive (1 of 3) Financial sustainability 01 Pioneering the automation of clinical record coding Quality of clinical 07 02 Revenue assurance The automation of clinical analytics record coding – the ability to produce high quality data in Drivers for real ti
Slide 15: AI Product Innovation: Pathway to Coding automation (2 of 3)
AI Product Innovation: Pathway to Coding automation (2 of 3) Localised baseline coding quality and Integrated Coding Platform (Assisted Automated efficiency review coding, PICQ and RISQ) clinical coding ▪ Data maturity score for each region and each ▪ Automation of coding quality assurance ▪ Prototy
Slide 16: The Integrated Coding Platform: assisted and automated (3 of 3)
AI Product innovation The Integrated Coding Platform: assisted and automated (3 of 3) Assisted Coding Coding Guidance Revenue Optimisation ito e Cli eries mon manc g rin nic Qu al or Perf Record Automated Triage Data Grouper Record final PAS/Billing Quality e tim kforc tion R e p h ma r ben ▪ PAS is
Slide 17: Beamtree: Core International Markets
Beamtree: Core International Markets United Kingdom FY24: Continued strengthening Canada • 68m population relationship with Lean including co- investment into Integrated Coding • 39m population • $377b health expenditure Platform. • $331b health expenditure FY25: Expand Coding opportunities (PICQ an
Slide 18: International Expansion
International Expansion FY 24 FY 25 • Delivery of clinical decision support product POC’S • Development & deployment of UK ready coding at 2 NHS Trusts products, benchmarking and analytics solutions UK • Quality of coding reviews at 6 NHS Trusts & across broader NHS Integrated Care Boards • Attainme
Slide 19: FY24 Financial Results
FY24 Financial Results Copyright © Beamtree Holdings Limited – All Rights Reserved 18
Slide 20: FY24 Summary Profit and Loss
FY24 Summary Profit and Loss FY23 FY24 Annual Recurring Revenue 22.8 25.5 Diagnostic 6.3 6.8 Coding & data quality assurance 5.2 8.4 Group Revenue Clinical decision support 0.7 0.4 Knowledge networks Total Revenue 10.6 22.8 11.9 27.6 +21% Expenses – people (17.3) (19.7) Expenses – non people (6.9) (
Slide 21: Strong Track Record of Revenue Growth
Strong Track Record of Revenue Growth ($’M) Organic Growth +15% +14% +20% +21% +21% 27.6 +38% 22.8 +97% 10.7 39% 7.3 16.5 4.1 25% +103% 8.4 16.9 61% 15.5 3.6 12.4 75% 4.1 2.2 4.8 1.9 FY20 FY21 FY22 FY23 FY24 Australia International Copyright © Beamtree Holdings Limited – All Rights Reserved 20
Slide 22: Controlled Operating Expense Growth
Controlled Operating Expense Growth ($’M) Organic Growth +85% +7% +12% 27.2 24.2 7.5 28% 20.6 +9% YoY 6.9 6.3 19.7 7.5 17.3 72% 14.2 2.8 +14% YoY 4.7 FY21 FY22 FY23 FY24 Employment Non-employment Copyright © Beamtree Holdings Limited – All Rights Reserved 21
Slide 23: Strong Profitability Improvement
Strong Profitability Improvement Annual Operating Profit Trend 2H Operating Profit Trend 1.0 0.4 (0.5) (1.4) 138% (2.6) 110% (4.0) FY22 FY23 FY24 2H FY22 2H FY23 2H FY24 Growth rate from FY22 to FY24 Copyright © Beamtree Holdings Limited – All Rights Reserved 22
Slide 24: Reported EBITDA
Reported EBITDA Reported EBITDA Operating Profit to EBITDA Reconciliation (0.5) FY23 FY24 (1.2) Operating profit (1.4) 0.4 Non-operating expenses (cash) (2.3) Restructuring and other non-operating costs (0.4) (0.1) 79% Impact of AASB 16 (property lease costs) 0.4 0.3 Total non-operating expenses (ca
Slide 25: Balance Sheet
Balance Sheet FY23 FY24 Current assets Cash and cash equivalents 8.8 5.0 Trade and other receivables 5.3 6.3 Strong Cash Position Contract assets 0.3 0.2 Total current assets Non-current assets 14.4 11.5 $5m Property, plant and equipment 0.3 0.2 Right-of-use assets 0.2 1.2 Intangibles 45.7 44.7 Defe
Slide 26: Cashflow
Cashflow FY23 FY24 Cash flows from operating activities Receipts from customers (inclusive of GST) 25.4 30.9 Payments to suppliers and employees (inclusive of GST) (25.4) (31.5) Strong cashflow in 2H R&D incentive received 0.8 0.0 (Dec 23 $5.1m vs June 24 $5.0m) Interest received 0.0 0.1 Income taxe
Slide 27: FY25 Outlook and Targets
FY25 Outlook and Targets Copyright © Beamtree Holdings Limited – All Rights Reserved 26
Slide 28: FY25 Outlook and Targets
FY25 Outlook and Targets Management reaffirms long term Continuing revenue growth Cost growth % targeted to be lower outlook of delivering annual of +20% than revenue growth % recurring revenue of $60m by 2026 Geographical FY25 Priorities Growth • ANZ: Pricing discipline, cross selling, rollout of n
Slide 29: Thank you
Thank you 28
Slide 30: Appendix: 5 Year Growth Record
Appendix: 5 Year Growth Record CAGR 45% CAGR 61% Annual Recurring Revenue Reported Revenue 27.6 25.5 22.8 22.8 18.2 16.5 8.4 5.8 6.7 4… FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 CAGR 49% International Revenue 10.7 7.3 3.6 4.1 2.2 FY20 FY21 FY22 FY23 FY24 *EBITDA Copyright © Beamtree Holdings